Last updated: 11/07/2018 18:50:39
A multicentre, randomised, double-blind, double-dummy, parallel-group, 12-week, active control comparison of the salmeterol/fluticasone propionate combination product (50/100mcg strength) bd via the DISKUS/ACCUHALERinhaler with …
Clinicaltrials.gov ID
Not applicable
EudraCT ID
Not applicable
EU CT Number
Not applicable
Trial status
Study complete
Study complete
Trial overview
Official title: A multicentre, randomised, double-blind, double-dummy, parallel-group, 12-week, active control comparison of the salmeterol/fluticasone propionate combination product (50/100mcg strength) bd via the DISKUS/ACCUHALERinhaler with …
Trial description: A multicentre, randomised, double-blind, double-dummy, parallel-group, 12-week, active control comparison of the salmeterol/fluticasone propionate combination product (50/100mcg strength) bd via the DISKUS/ACCUHALERinhaler with …
Primary purpose:
Not applicable
Trial design:
Not applicable
Masking:
Not applicable
Allocation:
Not applicable
Primary outcomes:
Not applicable
Secondary outcomes:
Not applicable
Interventions:
Not applicable
Enrollment:
Not applicable
Primary completion date:
Not applicable
Observational study model:
Not applicable
Time perspective:
Not applicable
Clinical publications:
Abstract: Comparative efficacy of asthma treatments: impact of allergic vs non-allergic status on response to therapy. K. Rickard P. Dorinsky S. Yancey A. Emmett. 60th Anniversary Meeting of the American Academy of Allergy, Asthma and Immunology 3/7/2003 Denver CO
Abstract: Greater responder rate to fluticasone propionate/salmeterol combination over montelukast plus fluticasone in asthma. E.D. Bateman, M. Akveld M. Ho. 99th International Conference of the American Thoracic Society 5/16/2003 Seattle WA
Abstract: Salmeterol/fluticasone propionate combination 50/100 î¼g bid is more effective than fluticasone propionate 100 î¼g bid plus montelukast 10 mg once daily in reducing exacerbations. Gold, M., JA?gi, R., Mulder, P. G. H., and Akveld, M. L. M. 11th Annual Congress of the European Respiratory Society 9/22/2001 Berlin; Germany
Abstract: The salmeterol/fluticasone propionate combination 50/100 mcg bid is more effective than the combiantion of fluticasone propionate 100mcg bid plus montelukast 10 mg once daily. Ringdal, N, Weber, H H, Eliraz, A, Pruzinec, P, and Akveld, M L M Bateman E American Lung Association/American Thoracic Society 97th International Conference 5/18/2001 San Francisco CA
Abstract: The salmeterol/fluticasone propionate combination 50/100 î¼g bid is more effective than oral montelukast 10 mg od as a first line therapy in mild and moderate asthmatics. Rickard, K., Dorinsky, P. M., Knobil, K., Pepsin, P., and Akveld, M. L. M. 11th Annual Congress of the European Respiratory Society 9/22/2001 Berlin; Germany
Bateman ED, Akveld M, Ho M. Greater responder rate to fluticasone propionate/salmeterol combination over montelukast plus fluticasone in asthma. Am J Respir Crit Care Med 2003; 167 (7): A367
Gold M, Jogi R, Mulder PGH, Akveld MLM. Salmeterol/fluticasone propionate combination 50/100 mcg bid is more effective than fluticasone propionate 100 mcg bid plus montelukast 10 mg once daily in reducing exacerbations. Eur Respir J 2001; 18 (Suppl 33): 262s
Pieters WR, Wilson KK, Smith HCE, Tamminga JJ. Cost-effectiveness of fluticasone propionate/salmeterol combination product and fluticasone propionate/ montelukast in asthma. Am J Respir Crit Care Med 2001; 163 (5 part 2): A643
Pieters WR, Wilson KK, Smith HCE, et al. Salmeterol/fluticasone propionate versus fluticasone propionate plus montelukast: A cost-effective comparison for asthma. Treatments in Respiratory Medicine 2005;4(2):129-138.
Ringdal N, Eliraz A, Pruzinec P, Weber HH, Mulder PGH, Akveld M, et al (on behalf of an international study group). The salmeterol fluticasone combination is more effective than fluticasone plus oral montelukast in asthma. Respir Med 2003; 97: 234-241
Ringdal N, Weber HH, Eliraz A, Pruzinec P, Akveld MLM, Bateman E. The salmeterol/fluticasone propionate combination 50/100 mcg bid is more effective than the combination of fluticasone propionate 100 mcg bid plus montelukast 10 mg once daily. Am J Respir Crit Care Med 2001; 163 (5 part 2): A865
Medical condition
Asthma
Product
fluticasone propionate/salmeterol
Collaborators
Not applicable
Study date(s)
March 1999 to May 2000
Type
Not applicable
Phase
4
Participation criteria
Sex
Not applicable
Age
Not applicable
Accepts healthy volunteers
Not applicable
Inclusion and exclusion criteria
Trial location(s)
This study does not involve prospective enrollment of participants.
Study documents
Scientific result summary
Available language(s): English
If you wish to request for full study report, please contact - [email protected]
Results overview
Not applicable
Recruitment status
Study complete
Actual primary completion date
Not applicable
Actual study completion date
2000-15-05
Plain language summaries
Plain language summaries of clinical trial results for Phase 2-4 clinical trials that were initiated on or after January 2022 will be posted by GSK within one year following study completion.
Additional information about the trial
Not applicable
Participate in clinical trial
Access to clinical trial data by researchers
Visit website